Press Releases
August 14, 2026
NurExone Reports New Preclinical Tissue-Analysis Data Supporting Potential Neuroprotective Effect of ExoPTEN in Acute Spinal Cord Injury Animal Model
August 12, 2026
NurExone Announces Binding MOU with Made Scientific for U.S. GMP Manufacturing and Commercial Supply Partnership
July 30, 2026
NurExone Launches Bioprocess Optimization Initiative to Support Commercial and Clinical Readiness
July 28, 2026
Corporate Updates – NurExone appoints Mr. David Stolick to the Board of Directors
June 24, 2026
Exo-Top, NurExone’s wholly owned U.S. Subsidiary, Enters Into Binding MOU For Naïve Exosome Distribution in Mexico
June 1, 2026
NurExone Announces First Quarter 2026 Financial Results and Provides Corporate Update
May 27, 2026
NurExone Receives Notice of Patent Grant in South Korea Covering ExoPTEN Technology
May 14, 2026
NurExone Advances to Stage 2 of EU-Backed EIT Health Catapult Programme 2026
April 28, 2026
Australian Patent Granted to NurExone Covering Stem Cell-Derived Exosome Production
April 26, 2026
The Biotech Event Accelerating Fresh Ideas, Partnerships and Opportunities 2026
April 16, 2026
NurExone Biologic Inc. Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update
April 7, 2026
NurExone Biologic’s U.S. Subsidiary Exo-Top and Florida-Based BioXtek Sign Strategic LOI for Exosome Manufacturing and Commercialization
April 1, 2026
NurExone Receives First Place in Healthcare at BOLD Awards VII and Engages Investor Brand Network to Support Awareness Strategy
March 4, 2026
NurExone to Showcase Its Regenerative Medicine Platform at NANO.IL.2026 and Advanced Therapies Congress in March 2026 and Provides Corporate Update
February 12, 2026
NurExone Biologic Advances Manufacturing and Regulatory Roadmap with Independent Batch Consistency Results for Exosome Production
February 1, 2026
NurExone Appoints Eyal Gabbai to Board, Adding Large-Scale Healthcare System and Capital Markets Expertise
December 19, 2025
NurExone Reports Anti-Inflammatory Activity of Its Exosomes in Lab Analysis
December 12, 2025
NurExone Plans Small-Scale of ExoPTEN Clinical Manufacturing in Preparation for FUTURE First in Human USE Pathways
November 30, 2025
NurExone Biologic Inc. Announces Third Quarter 2025 Financial Results and Provides Corporate Update
November 18, 2025
The Galien Foundation Announces 2025 Prix Galien Bridges Awards Nominees for “Best Bridge-Builder Institution,” “Best Biomedical Product,” “Best Medical Technology/AI Advances in Human Health,” “Best Product for Rare/Orphan Diseases,” and “Best Public Sector Innovation”
November 12, 2025
NurExone Secures over C$3.18 Million Through Accelerated Warrant Exercises
November 3, 2025
NurExone Accepted into ARMI’s BioFab Startup Lab Strengthening U.S Position in Regenerative Manufacturing
October 21, 2025
NurExone Invited Presenter at Precision EV Forum in Cambridge, UK
October 8, 2025
NurExone Demonstrates Reproducible, Dose-Dependent Vision Recovery in Preclinical Glaucoma Model
September 17, 2025
NurExone Planning to Establish First U.S. Commercial Manufacturing Facility in Indiana
September 11, 2025
NurExone Biologic Announces Corporate Updates including Israel Patent Grant and Private Placement Closing
September 9, 2025
NurExone Receives U.S. Patent Allowance for Exosome Manufacturing, Strengthening Supply Chain Readiness
August 28, 2025
NurExone Biologic Inc. Announces Second Quarter 2025 Financial Results
August 24, 2025
NurExone Biologic Announces Preclinical Evidence of Structural Repair in Injured Spinal Cord Tissue following ExoPTEN Treatment
August 8, 2025
NurExone’s Exosomes Show Stronger Healing Potential Than Industry Standard
July 27, 2025
NurExone Biologic Finalist in Falling Walls Venture 2025 Global Platform Showcasing The World’s Most Promising Science-Based Start-Ups
July 8, 2025
New ExoPTEN Preclinical Study Indicates Significant Improvement in Walking Quality in Spinal Cord Injury Model
June 20, 2025
NurExone Advances U.S. Growth Strategy with Acceptance into Prestigious ARMI HealthTech Hub Accelerator and Provides Corporate Update
June 5, 2025
NurExone Strengthens Path to Clinical Trials for ExoPTEN with New Manufacturing Process Validation
May 30, 2025
NurExone Announces Clinical Trial Plans for Acute Spinal Cord Injury Therapy at Annual Meeting of American Spinal Injury Association
May 27, 2025
NurExone Biologic Inc. Announces First Quarter 2025 Financial Results and Provides Corporate Update
May 12, 2025
NurExone Advances Vision Restoration Strategy with Preclinical Data Presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2025
May 6, 2025
NurExone Expands European Engagement with Investor Events in Germany and Switzerland
April 27, 2025
NurExone to Showcase Breakthrough in Facial Nerve Regeneration at ISEV 2025
April 23, 2025
NurExone Appoints Biotech Industry Leader – Jacob Licht to Lead U.S. Operations and Exo-Top Manufacturing Expansion and Completes Continuance into Ontario
April 10, 2025
NurExone Biologic Inc. Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update
April 4, 2025
NurExone Biologic Announces U.S. Uplisting Intention and Closes C$2.3 Million Private Placement
March 16, 2025
ExoPTEN Preclinical Study Demonstrates Significant Potential for Enhancing Motor Function, Blood Flow, and Spinal Cord Injury Recovery
February 16, 2025
NurExone Biologic Continues Expansion of U.S. Presence and Awareness with Prestigious Conference Presentation
February 6, 2025
NurExone Forms Exo-Top Inc. in the U.S. for Exosome Manufacture and Commercialization
January 22, 2025
NurExone Secures C$1.2 Million through Warrant Exercises and Completion of Private Placement and Appoints New R&D Director
December 8, 2024
NurExone Announces Promising Preclinical Results in Restoring Vision After Optic Nerve Damage
November 28, 2024
NurExone Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 14, 2024
NurExone Biologic Secures EMA Orphan Status for ExoPTEN in Spinal Cord Injury, Accelerating Pathway to European Markets
November 4, 2024
NurExone Biologic Closes Final Tranche of Non-Brokered Private Placement and Provides Corporate Update
October 27, 2024
NurExone’s Regenerative Medicine Therapies To Be Recognized at Fall Conferences in the USA
September 29, 2024
NurExone Biologic Announces Private Placement of up to $2M and Closes First Tranche for $1.61M
September 15, 2024
NurExone Biologic Extends Global Reach with Presentations at Industry-Leading Conferences
September 9, 2024
NurExone Demonstrates Extended Therapeutic Window of ExoPTEN Post Spinal-Cord Injury in Preclinical Study
August 25, 2024
NurExone Biologic Invited to Present Groundbreaking ExoPTEN Therapy at Prestigious September Conferences
August 21, 2024
NurExone Biologic Achieves Key Milestone in Support of Robust Exosome Manufacturing Process
August 11, 2024
NurExone’s ExoPTEN, loaded with siRNA, Demonstrates Ability to Target Injury and Inflammation Sites – New Study
July 21, 2024
Promising Preliminary Results in Optic Nerve Recovery Study of NurExone’s first product ExoPTEN for Glaucoma
July 7, 2024
Updates from NurExone: Growth Conference Presentation and Website Relaunch
June 30, 2024
NurExone’s ExoPTEN Being Studied as Glaucoma Treatment for US$3.4 Billion Market
June 23, 2024
On Path to First-in-Human Study, NurExone Engages Prominent Expert in Biological Drug Development
June 5, 2024
NurExone Announces Voting Results from 2024 Annual Meeting of Shareholders
June 3, 2024
NurExone Reports First Quarter 2024 Financial Results and Provides Corporate Update, moving forward with FDA guidelines for the Human Trials
May 19, 2024
NurExone Welcomes Biopharma Exec Dr. Ram Petter to Drive Strategic Collaborations
April 19, 2024
NurExone Biologic Inc. Announces Strategic Expansion to US Financial Markets with Approval of OTCQB Listing Application and DTC Eligibility
April 19, 2024
NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative Medicine
April 2, 2024
NurExone Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Company Update
March 17, 2024
NurExone’s Strategic Update: Submission of OTCQB Listing Application to Initiate US financial presence
March 10, 2024
NurExone establishing State-of-the-Art Research and Development Facility in Haifa, Israel
March 1, 2024
NurExone Presenting Novel Regulatory Pathways for Exosomes Therapies at Global Summit
February 4, 2024
Nurexone Biologic Initiates European Orphan Drug Designation Process Following U.S. Grant
January 17, 2024
NurExone and Inteligex Kick Off Chronic Spinal Cord Injury Research for Multi-Billion Dollar Healthcare Market
January 7, 2024
NurExone Announces Closing of a Private Placement for Gross Proceeds of Approximately CAD$2 Million
December 27, 2023
NurExone Biologic Extends Spinal Cord Injury Therapy Portfolio With New RNA Sequences Promoting Healing and Regeneration
November 28, 2023
NurExone Reports Third Quarter 2023 Financial Results and Provides Corporate Update
October 31, 2023
NurExone Biologic Receives FDA Orphan-Drug Designation, Accelerating Development of ExoPTEN therapy for Acute Spinal Cord Injury Treatment
October 31, 2023
Appointment of Professor Teo Forcht Dagi to Scientific Advisory Board and Advisory Committee
October 12, 2023
A next-generation therapeutic approach for patients after spinal cord injuries
October 12, 2023
NurExone Secures Eureka Grant for Collaborative Partnership to Expand to Chronic Spinal Cord Injury Therapy
September 13, 2023
NurExone Moves Forward Towards Human Clinical Trials, Completes Pre-IND Meeting with the FDA for Proprietary ExoPTEN Drug
September 7, 2023
NurExone Announces Closing of Second Tranche of Private Placement, bringing total raise at this round to approximately CAD$1.5M
August 29, 2023
NurExone Reports Second Quarter 2023 Financial Results and Provides Corporate Update
June 26, 2023
Regeneration and Reinnervation of Spinal Cord in Rats Treated with NurExone’s Intranasal ExoPTEN
June 26, 2023
NurExone and Particle Metrix Announce Collaboration in Extracellular Vesicles Analysis Using State-of-the-art Analytic Device
May 29, 2023
NurExone Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 29, 2023
NurExone Granted U.S. Patent for Technology and Drug Composition of Exo-PTEN, Designed for Treating Acute Spinal Cord Injuries
May 29, 2023
NurExone Announces Equity Incentive Plan Grants and Director Resignation
April 2, 2023
NurExone Announces Q4 and Full-year 2022 Financial Results and Provides Company Update, Highlighting 143.9% Scientific Research Investment Growth
March 23, 2023
NurExone Biologic Reports Additional Positive Preclinical Trial Outcomes with ExoPTEN: 75% of Paralyzed Rats Show Recovery after Acute Spinal Cord Injury Study
February 21, 2023
NurExone Announces Interim Positive Results of Internal Preclinical Study of Proprietary ExoPTEN Drug
February 21, 2023
NurExone Biologic Inc. Emerges as a Promising Investment Opportunity in Biotechnology
January 17, 2023
United States Patent Office Allows Patent to Exosome Biomedical Company NurExone
December 5, 2022
NurExone Biologic Successfully Demonstrates its Patent-Pending Platform Technology for Loading Exosomes with Therapeutic Molecules
November 30, 2022
NurExone Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 14, 2022
NurExone Announces Completion of Securities for Debt Settlements
November 7, 2022
NurExone Announces Plan to Submit Pre-Investigational New Drug Meeting Request to U.S. Food and Drug Administration
October 30, 2022
NurExone Announces Productivity and Quality Pilot Results of Patent-Pending Process for 3D Scaled Up Exosome Production
October 23, 2022
NurExone Signs Letter of Intent with Nanometrix For its Exosome and Cargo Molecular Profiling AI-Driven Technology
October 19, 2022
NurExone Announces Scientific Survey Results of Proprietary Exosome-based Technology
October 19, 2022
NurExone Announces Letter of Intent for International Strategic Collaboration with denovoMATRIX Towards Large-Scale Exosome Production
September 19, 2022
NurExone Announces Securities Issuing at Premium over Current Share Price to Settle EnerSpar’s Debts Prior to RTO Transaction
September 19, 2022
NurExone Reports Second Quarter 2022 Financial Results and Provides Business Update
August 30, 2022
James Richardson, the Former CEO of EnerSpar, Updates Shareholders After the Completion of RTO with NurExone Biologic
July 19, 2022
NurExone Exosomes to Be Used in Cutting Edge Molecular Research at Hebrew University’s Burstyn-Cohen Lab
July 12, 2022
NurExone to Collaborate with Polyrizon for Intranasal Administration of Cutting-Edge Exosome-Therapy
July 1, 2022
NurExone Biologic Inc. to Begin Trading on TSX Venture Exchange and Retains Market Maker
July 1, 2022
NurExone Biologic Inc. (Formerly, Enerspar Corp.) Announces Completion of Reverse Takeover Transaction
July 1, 2022
EnerSpar and NurExone Announce Conditional Acceptance of Proposed Reverse Takeover Transaction
July 1, 2022
EnerSpar and Israeli-Based Nurexone Provide Update on Progress to Closing RTO
March 13, 2022